Lumos Pharma (LUMO) Competitors $4.33 +0.03 (+0.70%) (As of 11/14/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends LUMO vs. EQ, CNTX, PBYI, VTYX, SCLX, CGEN, OTLK, IVA, RPTX, and CADLShould you be buying Lumos Pharma stock or one of its competitors? The main competitors of Lumos Pharma include Equillium (EQ), Context Therapeutics (CNTX), Puma Biotechnology (PBYI), Ventyx Biosciences (VTYX), Scilex (SCLX), Compugen (CGEN), Outlook Therapeutics (OTLK), Inventiva (IVA), Repare Therapeutics (RPTX), and Candel Therapeutics (CADL). These companies are all part of the "pharmaceutical products" industry. Lumos Pharma vs. Equillium Context Therapeutics Puma Biotechnology Ventyx Biosciences Scilex Compugen Outlook Therapeutics Inventiva Repare Therapeutics Candel Therapeutics Lumos Pharma (NASDAQ:LUMO) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability. Is LUMO or EQ more profitable? Equillium has a net margin of -19.51% compared to Lumos Pharma's net margin of -1,583.49%. Equillium's return on equity of -36.88% beat Lumos Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Lumos Pharma-1,583.49% -233.03% -129.88% Equillium -19.51%-36.88%-17.31% Do insiders and institutionals have more ownership in LUMO or EQ? 34.0% of Lumos Pharma shares are held by institutional investors. Comparatively, 27.1% of Equillium shares are held by institutional investors. 25.4% of Lumos Pharma shares are held by insiders. Comparatively, 30.3% of Equillium shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community believe in LUMO or EQ? Lumos Pharma received 1 more outperform votes than Equillium when rated by MarketBeat users. However, 83.72% of users gave Equillium an outperform vote while only 75.51% of users gave Lumos Pharma an outperform vote. CompanyUnderperformOutperformLumos PharmaOutperform Votes3775.51% Underperform Votes1224.49% EquilliumOutperform Votes3683.72% Underperform Votes716.28% Which has preferable earnings & valuation, LUMO or EQ? Equillium has higher revenue and earnings than Lumos Pharma. Equillium is trading at a lower price-to-earnings ratio than Lumos Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLumos Pharma$2.05M18.27-$34.03M-$4.29-1.01Equillium$36.08M0.67-$13.34M-$0.25-2.74 Does the media prefer LUMO or EQ? In the previous week, Lumos Pharma had 1 more articles in the media than Equillium. MarketBeat recorded 5 mentions for Lumos Pharma and 4 mentions for Equillium. Equillium's average media sentiment score of 0.72 beat Lumos Pharma's score of -0.10 indicating that Equillium is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lumos Pharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Equillium 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer LUMO or EQ? Lumos Pharma presently has a consensus price target of $8.63, suggesting a potential upside of 99.19%. Equillium has a consensus price target of $5.00, suggesting a potential upside of 630.78%. Given Equillium's higher probable upside, analysts plainly believe Equillium is more favorable than Lumos Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lumos Pharma 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00Equillium 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, LUMO or EQ? Lumos Pharma has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Equillium has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500. SummaryEquillium beats Lumos Pharma on 11 of the 17 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Lumos Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LUMO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LUMO vs. The Competition Export to ExcelMetricLumos PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.45M$7.01B$5.34B$8.88BDividend YieldN/A8.03%4.98%4.04%P/E Ratio-1.0111.36132.1317.45Price / Sales18.27376.441,259.0698.78Price / CashN/A49.2239.1436.42Price / Book7.609.076.265.86Net Income-$34.03M$153.49M$118.47M$224.86M7 Day Performance0.12%-2.22%-2.23%-0.93%1 Month Performance11.03%7.48%2.38%3.66%1 Year Performance37.90%37.69%35.45%26.41% Lumos Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LUMOLumos Pharma3.0146 of 5 stars$4.33+0.7%$8.63+99.2%+38.7%$37.45M$2.05M-1.0130Short Interest ↓EQEquillium3.3279 of 5 stars$0.78-8.2%N/A+56.1%$27.64M$36.08M-3.1240Short Interest ↓Gap DownCNTXContext Therapeutics2.4184 of 5 stars$1.97-3.9%N/A+87.6%$147.75MN/A-2.167Analyst RevisionPBYIPuma Biotechnology3.7559 of 5 stars$2.97-7.5%N/A-21.8%$145.80M$235.60M6.19185Earnings ReportAnalyst UpgradeVTYXVentyx Biosciences2.41 of 5 stars$2.02-3.8%N/A-15.1%$142.83MN/A-0.8673Analyst ForecastSCLXScilex3.4734 of 5 stars$0.74-3.9%N/A-42.2%$141.93M$46.74M-0.5280Gap UpCGENCompugen2.7734 of 5 stars$1.59-0.6%N/A+200.0%$141.89M$33.46M79.5068Earnings ReportShort Interest ↓News CoverageOTLKOutlook Therapeutics1.9866 of 5 stars$5.96-4.9%N/A-26.3%$141.01MN/A-0.5620Positive NewsIVAInventiva3.3793 of 5 stars$2.66+0.8%N/A-26.5%$139.60M$18.91M0.00100Analyst ForecastShort Interest ↓News CoverageRPTXRepare Therapeutics3.3638 of 5 stars$3.26-6.9%N/A-12.8%$138.58M$51.13M-1.63180News CoverageCADLCandel Therapeutics0.2626 of 5 stars$4.29-4.0%N/A+371.6%$137.62M$120,000.00-2.5460Short Interest ↑ Related Companies and Tools Related Companies Equillium Competitors Context Therapeutics Competitors Puma Biotechnology Competitors Ventyx Biosciences Competitors Scilex Competitors Compugen Competitors Outlook Therapeutics Competitors Inventiva Competitors Repare Therapeutics Competitors Candel Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LUMO) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThis small cap’s electric marine powertrain broke the world speed recordThe future of marine propulsion has arrived-powered by a $2 billion powerhouse. In collaboration with McLar...The Tomorrow Investor | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredElon Musk’s $30 Billion Trump Bet Pays Off—What’s Next?Elon Musk bet big on Trump's victory, and that gamble has already added over $30 billion to his net worth in a...InvestorPlace | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lumos Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lumos Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LUMO Stock Alerts